Recent research suggests that measuring standard cardiac biomarkers does not help in identifying asymptomatic severe aortic stenosis patients who would benefit from early transcatheter aortic valve replacement (TAVR). Traditionally, treatment was delayed until symptoms appeared, but this study indicates that proactive planning for valve replacement within six months is crucial. The EARLY TAVR trial established that early intervention greatly improves patient outcomes compared to delayed treatment, emphasizing the need for reconsidering traditional approaches to managing severe aortic stenosis.
Measuring standard cardiac biomarkers did not predict whether patients with asymptomatic severe aortic stenosis would benefit from nonsurgical aortic valve replacement.
Waiting for symptoms is not the best strategy; planning for a valve replacement in the next six months is recommended before symptoms develop.
The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement improved outcomes for patients with severe aortic stenosis versus delayed treatment.
More than 13 percent of Americans over 75 will develop severe aortic stenosis, leading to severe health risks if untreated.
#aortic-stenosis #heart-disease #cardiology #transcatheter-aortic-valve-replacement #clinical-research
Collection
[
|
...
]